Fingolimod significantly alleviated motor function deficits in both PD mouse models, reduced the loss of tyrosine hydroxylase-positive neurons in the substantia nigra, decreased striatal dopamine and its metabolite levels, maintained ERK phosphorylation levels, and reduced cleaved caspase 3 expression. This evidence concerns the gene TH and Parkinson disease.